Louisiana court rejects Eisai, Arena motion to dismiss Belviq cancer lawsuit

A Louisiana federal court has rejected a motion by Eisai and Arena Pharmaceuticals to dismiss a Belviq lawsuit filed by a woman who was diagnosed with cancer after using the diet drug. The case is one of numerous lawsuits that have been filed against the two drugmakers in the U.S. by patients who were prescribed Belviq (lorcaserin) for weight loss and later diagnosed with cancer. (more…)

By |2021-01-29T14:53:56+00:00January 26th, 2021|Belviq|Comments Off on Louisiana court rejects Eisai, Arena motion to dismiss Belviq cancer lawsuit

Missouri lawsuit alleges weight loss drug Belviq caused breast cancer diagnosis

A Missouri woman has filed a lawsuit against the manufacturers of Belviq (lorcaserin). The lawsuit alleges that after years of taking the weight loss drug, Amy Davis was diagnosed with breast cancer, which she alleges was caused by the medication. (more…)

By |2021-01-07T16:45:22+00:00January 7th, 2021|Belviq|Comments Off on Missouri lawsuit alleges weight loss drug Belviq caused breast cancer diagnosis

FDA withdraws Belviq, Belviq XR approval due to cancer risks

The Food and Drug Administration has formally withdrawn approval of the weight loss drugs Belviq and Belviq XR (lorcaserin), citing the increased cancer risk associated with these medications. The FDA had previously ordered the manufacturers of Belviq, Arena Pharmaceuticals and Eisai, to withdraw the two formulations of the drug in February after studies showed that patients who used the diet medications were more likely to develop cancer. (more…)

By |2020-12-22T14:03:59+00:00November 30th, 2020|Belviq|Comments Off on FDA withdraws Belviq, Belviq XR approval due to cancer risks

Belviq permanently banned by Taiwanese FDA due to increased cancer risk

The Food and Drug Administration of Taiwan announced that it will permanently ban the weight loss medication Belviq (lorcaserin), citing evidence linking the drug to an increased cancer risk. Clinical trial data released earlier this year by the manufacturer of Belviq, Eisai Inc., showed that patients who use the weight loss drug face an increased risk of developing pancreatic, colorectal, and lung cancer. (more…)

By |2020-10-26T17:31:45+00:00October 26th, 2020|Belviq|Comments Off on Belviq permanently banned by Taiwanese FDA due to increased cancer risk

Belviq Users With Cancer May Qualify to File a Lawsuit

Consumers who used the weight loss drugs Belviq or Belviq XR and were diagnosed with cancer may qualify to file a lawsuit and receive compensation for their illness. Several lawsuits by patients who were diagnosed with cancer have been filed against Eisai Inc. and Arena Pharmaceuticals — the manufacturers of Belviq — after the weight loss drug was recalled by the FDA. (more…)

By |2020-10-19T16:50:28+00:00September 30th, 2020|Belviq|Comments Off on Belviq Users With Cancer May Qualify to File a Lawsuit

Belviq lawsuits allege weight loss drug linked to increased cancer risk

The manufacturers of the weight loss drug Belviq (lorcaserin) — Eisai Inc. and Arena Pharmaceuticals — are facing several lawsuits over allegations that the medication is linked to an increased cancer risk. Patients who used Belviq to lose weight and have been diagnosed with cancer may qualify to take legal action and receive compensation for their injuries. (more…)

By |2020-10-19T16:49:19+00:00August 26th, 2020|Belviq|Comments Off on Belviq lawsuits allege weight loss drug linked to increased cancer risk

Class action lawsuit alleges Eisai, Arena hid cancer risk of Belviq weight loss drug

Eisai Inc. and Arena Pharmaceuticals — the makers of the drugs Belviq and Belviq XR (lorcaserin) — face a class action lawsuit alleging that the weight loss drugs increase the cancer risk of patients who used them. The lawsuits, filed in March at the U.S. District Court in White Plains, New York, seeks class action status on behalf of patients who used Belviq for weight loss and were diagnosed with cancer. (more…)

By |2020-10-22T14:54:42+00:00April 28th, 2020|Belviq|Comments Off on Class action lawsuit alleges Eisai, Arena hid cancer risk of Belviq weight loss drug

FDA orders recall of Belviq weight loss drug after study finds increased cancer risk

The U.S. Food and Drug Administration has requested that Eisai Inc., the manufacturer of the weight loss drug Belviq, recall the drug after a study found that it could increase the risk of developing pancreatic cancer, colorectal cancer, or lung cancer. (more…)

By |2020-10-19T16:40:08+00:00April 27th, 2020|Belviq|Comments Off on FDA orders recall of Belviq weight loss drug after study finds increased cancer risk
Go to Top